DPP4 Inhibitor Intervention on Post-stroke Cognitive Impairment in Ischemic Stroke Patients With Type 2 Diabetes

NCT07241897 · tracked via the Priya Life Science China tracker

Sponsor

Second Affiliated Hospital of Soochow University

Phase

Phase 3

Started

2025-12-15

Last updated

2025-11-21

Condition(s) studied

Ischemic StrokeDiabete Mellitus

Investigational drug(s) / intervention(s)

Sentagliptin Phosphate - single dosePlacebo

Sentagliptin Phosphate - single dose: Sentagliptin Phosphate 50 mg, once daily, plus metformin hydrochloride extended-release tablets (50 mg, two or three times daily). If blood glucose is still not well-controlled, sulfonylurea drugs may be added as needed.

Placebo: Placebo (identical in size, shape, color, appearance, and odor to Sentagliptin Phosphate, 50 mg, once daily) plus metformin hydrochloride extended-release tablets (50 mg, two or three times daily). If blood glucose is still not well-controlled, sulfonylurea drugs may be added as needed.

Study summary

Post-stroke cognitive impairment (PSCI) increases the risk of disability and mortality in stroke patients, thereby exacerbating the disease burden of stroke. Type 2 diabetes is a major risk factor for PSCI, and stroke patients with type 2 diabetes have a higher risk of developing PSCI. Despite the high incidence and severe impact of PSCI, effective intervention methods are still lacking. Identifying safe and effective drugs to improve cognitive function in stroke patients and reduce the risk of PSCI, especially for those with type 2 diabetes, is of significant importance and could help reduce the burden of stroke.

Dipeptidyl peptidase-4 (DPP4) inhibitors are first-line antidiabetic drugs, and several studies have shown that DPP4 inhibitors provide benefits beyond glucose control, including significantly improving cognitive function in patients with type 2 diabetes or slowing the progression of cognitive impairment. Our previous research found a significant negative correlation between baseline plasma soluble DPP4 (sDPP4) levels and the 90-day PSCI risk in ischemic stroke patients. Moreover, some studies indicate that DPP4 inhibitors can increase plasma sDPP4 levels. Based on this, we hypothesize that DPP4 inhibitors could be effective for PSCI intervention and may improve cognitive function post-stroke.

This project aims to conduct a multicenter, randomized, double-blind, placebo-controlled study. We will include patients with mild ischemic stroke combined with type 2 diabetes and provide continuous intervention with DPP4 inhibitors or a placebo for 180 days. Cognitive function in both groups will be assessed before and after intervention to determine if DPP4 inhibitors can improve cognitive function and reduce the risk of PSCI in ischemic stroke patients with type 2 diabetes. Clinical blood samples and imaging data will also be used to preliminarily explore potential mechanisms.

Eligibility

Sex

ALL

Min age

40 Years

Max age

75 Years

Healthy volunteers

Inclusion Criteria: 1. Mild ischemic stroke, defined as a National Institutes of Health Stroke Scale (NIHSS) score ≤ 5. 2. Coexisting type 2 diabetes with a disease duration of less than 5 years. 3. Ability to complete the MoCA, MMSE, and the NINDS-CSN-recommended 1-hour standardized neuropsychological test for VCI. 4. Age between 40 and 75 years. 5. Onset of stroke within the last 2 weeks. 6. Glycated hemoglobin (HbA1c) between 6.5% and 8.5%. 7. More than 9 years of education. 8. Informed consent signed by the patient or their family. Exclusion Criteria: 1. Coexisting dementia or severe cognitive impairment (MoCA \< 17). 2. Coexisting severe depression, defined as a Hamilton Depression Rating Scale (HAMD) score ≥ 20. 3. Prior use of cognitive-enhancing drugs, such as donepezil or memantine. 4. Allergy to DPP4 inhibitors. 5. Past or current use of DPP4 inhibitors. 6. Past or current use of GLP-1 agonists. 7. Type 1 diabetes, latent autoimmune diabetes in adults, secondary diabetes, malignant tumors, autoimmune diseases, or other endocrine-related diseases. 8. Moderate or severe liver or kidney dysfunction. 9. Chronic or acute pancreatitis. 10. Pregnancy or lactation. 11. Severe infection or severely impaired immune response. 12. Participation in other clinical trials. 13. Past or current use of insulin therapy.

Primary outcome measure(s)

Change in MoCA score before and after the 180-day intervention — 180 days
Change in MoCA score before and after the 180-day intervention

Trial sites (1)

Facility	City	Region	Status
Department of Neurology, Second Affiliated Hospital of Soochow University	Suzhou	Jiangsu

More Second Affiliated Hospital of Soochow University trials in China

A Clinical Study of Darcilil Combined With AI Combined With Pyrrotinib in the Treatment of TPBC Recruiting

Multi-Center Study of Natural History in Atypical Parkinsonian Syndromes (MAPS-NH) Recruiting

Evaluation of the Effect of Cordycepin on CD8+ Lymphocytopenia in Patients With Solid Tumors Recruiting

Repetitive Transcranial Magnetic Stimulation Therapy in Essential Tremor Recruiting

Light Therapy in Parkinson's Disease Recruiting

Other trials for the same condition

A Registry Study of Microcirculation Disorder After Cerebral Small Vessel Disease and Ischemic Stroke Starting soon

18F FDG and 68Ga FAPI PET/MR Imaging of Carotid Artery Plaque Vulnerability: A Clinical Study in Carotid Artery Plaque Patients Recruiting

Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR） Starting soon

Efficacy of Probucol Combined with Statins Treatment for Ischemic Stroke Recruiting

Timing of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07241897 on ClinicalTrials.gov ↗ ← All trials in China